Mental Health Mission Mood Disorder Cohort Study

NCT07189689 | Not Yet Recruiting

• 2 other identifiers: 18955345799
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments. Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.

Conditions

Depression - Major Depressive Disorder; Depression Bipolar; Treatment Resistant Depression

Keywords

Observational; Cohort; Depression; UK; Mission; Bipolar; TRD; Difficult-to-treat; Treatment resistant depression; Bipolar depression; cohort study; Observational study

Outcome Measures

Primary Outcomes (1)

• PHQ-9

  Patient Health Questionnaire - 9-item Depression scale. Scores range between 0-27, with higher scores indicating worse depression.

  Up to 36 months.

Other Outcomes (1)

• GAD-7

  Up to 36 months.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The current study aims to recruit adults aged 18 and over, currently residing in the UK with a diagnosis of major depressive disorder or bipolar disorder. The study will be advertised on social media and will allow people to self-refer to the study. We will also recruit via GP mail outs.

You may qualify if:

• Those aged 18 and above
• Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria
• Participant is willing and able to give informed consent for participation in the study
• Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team

You may not qualify if:

• Inability to complete study activities as assessed by the study team
• Presentation requires immediate emergency treatment
• Presentation requires clinical input not available within the research clinic

Sponsors & Collaborators

• University of Oxford: lead
• Newcastle University: collaborator
• University of Nottingham: collaborator
• University of Exeter: collaborator
• University of Southampton: collaborator
• University of Birmingham: collaborator
• University of Manchester: collaborator
• University of Liverpool: collaborator
• Avon and Wiltshire Mental Health Partnership NHS Trust: collaborator
• Cambridgeshire and Peterborough NHS Foundation Trust: collaborator
• University of Cambridge: collaborator
• Cardiff University: collaborator
• Cardiff and Vale University Health Board: collaborator
• University of Edinburgh: collaborator
• University of Glasgow: collaborator
• University College, London: collaborator
• Sheffield Health and Social Care NHS Foundation Trust: collaborator
• King's College London: collaborator
• Imperial College London: collaborator
• Oxford Health NHS FT: collaborator
• Cumbria, Northumberland, Tyne and Wear NHS FT: collaborator
• South London and Maudsley NHS FT: collaborator
• Nottinghamshire Healthcare NHS FT: collaborator
• Devon Partnership Trust: collaborator
• Hampshire and Isle of Wight Health NHS FT: collaborator
• Birmingham and Solihull Mental Health NHS Trust: collaborator
• Mersey Care NHS FT: collaborator
• NHS Lothian: collaborator
• NHS Greater Glasgow & Clyde: collaborator
• Camden & Islington NHS FT: collaborator
• West London NHS FT: collaborator
• Central and North West London NHS FT: collaborator

Study Sites (1)

Clinical Research Facility, Warneford Hospital

Oxford, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

DNA, RNA, serum, plasma and peripheral blood mononuclear cells (PBMC)

MeSH Terms

Conditions

Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Depression

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders; Depressive Disorder; Behavioral Symptoms; Behavior

Central Study Contacts

Alexander Lewis

CONTACT

+441865618152; alexander.lewis@psych.ox.ac.uk

Professor Michael Browning

CONTACT

michael.browning@psych.ox.ac.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 31, 2025
• First Posted: September 24, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): January 31, 2028
• Study Completion (Estimated): January 31, 2028
• Last Updated: October 3, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)